Pharma companies also face lockdown, sale of medicines for minor illnesses decreased
Due to the lockdown, patients are not reaching hospitals for treatment of minor illnesses. Due to this, medicines are being sold less.
Sales of drugs have also reduced due to the lockdown. There has been a decline in the sale of medicines for anti-infection, respiratory and stomach ailments in the country. Sales of these medicines have declined for the fourth consecutive month of lockdown due to Kovid-19 infection. Due to the lockdown, patients are not reaching hospitals for treatment of minor illnesses. According to the All India Origin Chemists and Druggists Association, sales of anti-infection medicines have come down since April.
Its average sales have fallen by 15 per cent since April. Sales fell 10 percent in July. Similarly, sales of Gestro Medicine have also been recorded. It has recorded a decline of 2.4 percent in July. Sales of medicines related to respiratory diseases have fallen by 2 per cent. It had registered a decline of 4.2 per cent in June. Only chronic diseases, such as diseases related to heart diseases, medicines are showing an increase. Its drug sales were up 13.9 percent in June. This growth rate was 13.1 percent in July.
Pharma industry growth slows
India’s pharma industry registered a growth of just 0.2 per cent in July. This month it increased to Rs 11,681 crore. Glaxo Smoothline, Alchem Laboratories and Abbott India have seen a significant decline in sales. The growth of the pharma market was 2.4 percent in June. The slowdown effect of this sector is clearly visible in the financial results of pharma companies. Sales of Sun Pharma and Lupine have declined. Lupine MD Nilesh Gupta said that the sale of its medicines in the Indian and American markets has suffered a setback due to the lockdown. Hence, the company’s quarterly results have been poor.
